> Detailanzeige

Sarkozy, Clémentine; Maurer, Matthew J.; Link, Brian K.; Ghesquieres, Hervé; Nicolas, Emmanuelle; Thompson, Carrie A.; Traverse-Glehen, Alexandra; Feldman, Andrew L.; Allmer, Cristine; Slager, Susan L.; Ansell, Stephen M.; Habermann, Thomas M.; Bachy, Emmanuel; Cerhan, James R.; Salles, Gilles

Cause of Death in Follicular Lymphoma in the First Decade of the Rituximab Era: A Pooled Analysis of French and US Cohorts

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Cause of Death in Follicular Lymphoma in the First Decade of the Rituximab Era: A Pooled Analysis of French and US Cohorts
  • Beteiligte: Sarkozy, Clémentine; Maurer, Matthew J.; Link, Brian K.; Ghesquieres, Hervé; Nicolas, Emmanuelle; Thompson, Carrie A.; Traverse-Glehen, Alexandra; Feldman, Andrew L.; Allmer, Cristine; Slager, Susan L.; Ansell, Stephen M.; Habermann, Thomas M.; Bachy, Emmanuel; Cerhan, James R.; Salles, Gilles
  • Erschienen: American Society of Clinical Oncology (ASCO), 2019
  • Erschienen in: Journal of Clinical Oncology
  • Sprache: Englisch
  • DOI: 10.1200/jco.18.00400
  • ISSN: 0732-183X; 1527-7755
  • Schlagwörter: Cancer Research ; Oncology
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:sec><jats:title>Purpose</jats:title><jats:p> Although the life expectancy of patients with follicular lymphoma (FL) has increased, little is known of their causes of death (CODs) in the rituximab era. </jats:p></jats:sec><jats:sec><jats:title>Patients and Methods</jats:title><jats:p> We pooled two cohorts of newly diagnosed patients with FL grade 1-3A. Patients were enrolled between 2001 and 2013 in two French referral institutions (N = 734; median follow-up 89 months) and 2002 and 2012 in the University of Iowa and Mayo Clinic Specialized Program of Research Excellence (SPORE; N = 920; median follow-up 84 months). COD was classified as being a result of lymphoma, other malignancy, treatment related, or all other causes. </jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p> Ten-year overall survival was comparable in the French (80%) and US (77%) cohorts. We were able to classify COD in 248 (88%) of 283 decedents. In the overall cohort, lymphoma was the most common COD, with a cumulative incidence of 10.3% at 10 years, followed by treatment-related mortality (3.0%), other malignancy (2.9%), other causes (2.2%), and unknown (3.0%). The 10-year cumulative incidence of death as a result of lymphoma or treatment was higher than death as a result of all other causes for each age group (including patients ≥ 70 years of age at diagnosis [25.4% v 16.6%]) Follicular Lymphoma International Prognostic Index score 3 to 5 (27.4% v 5.2%), but not Follicular Lymphoma International Prognostic Index score 0 to 1 (4.0% v 3.7%); for patients who failed to achieve event-free survival within 24 months from diagnosis (36.1% v 7.0%), but not for patients who achieved event-free survival within 24 months of diagnosis (6.7% v 5.7%); and for patients with a history of transformed FL (45.9% v 4.7%), but not among patients without (8.1% v 6.2%). Overall, 77 of 140 deaths as a result of lymphoma occurred in patients whose FL transformed after diagnosis. </jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p> Despite the improvement in overall survival in patients with FL in the rituximab era, their leading COD remains lymphoma, especially after disease transformation. Treatment-related mortality also represents a concern, which supports the need for less-toxic therapies. </jats:p></jats:sec>
  • Zugangsstatus: Freier Zugang